Berkeley Lights Announces the Global Emerging Pathogen Antibody Discovery Consortium (GEPAD) to Attack COVID-19 and Other Viruses
PR83431
EMERYVILLE, California, March 26, 2020 /PRNewswire=KYODO JBN/ --
-- In collaboration with Vanderbilt University Medical Center, La Jolla Institute for
Immunology and Emory University, viral neutralization workflows on the Berkeley Lights
platform are under accelerated development in response to the Coronavirus outbreak
Today Berkeley Lights, Inc., announced the Global Emerging Pathogen Antibody
Discovery Consortium (GEPAD) with founding members Dr. James Crowe and
Dr. Robert Carnahan at Vanderbilt University Medical Center, Dr. Erica Ollman
Saphire at La Jolla Institute for Immunology and Dr. Frances Eun-Hyung Lee at
Emory University with the aim to accelerate the discovery of neutralizing antibodies
from patient blood samples. Processing precious blood samples and fragile cells can be
challenging with traditional technologies. The consortium will leverage Berkeley Lights'
Beacon platform for antibody discovery using the blood of recovering patients as
the foundation for therapeutics, with COVID-19 as a first target.
Logo - https://mma.prnewswire.com/media/1078159/Berkeley_Lights_Logo.jpg
While researchers around the world are quickly characterizing the SARS-CoV-2
virus, the ability to screen single B cells expressing a SARS-CoV-2
neutralizing antibody remains a significant and time-consuming challenge. The
body has billions of B cells. After a patient recovers from SAR-CoV-2, they
generate many B cells specific for the virus; however, some B cells will make
antibodies that just bind to the virus but are not protective. Hence, finding
the special B cells that eliminate or neutralize the virus is exceedingly rare.
It is like finding a "needle in a haystack". The existing technologies can only
search for binders, not neutralizers – so researchers are forced to sequence
and re-express the antibody from non-specific B cells wasting significant time
and resources. The Beacon system and the viral neutralization assay is
designed to address this problem by directly screening single cells for
neutralizing function in a single day.
The primary goal of the GEPAD Consortium is to enable the quickest therapeutic
response to emerging pathogens. The GEPAD Consortium is requesting that anyone
interested in this viral neutralization workflow and advancing the state of the
art reach out and join them in forming a defensive barrier worldwide against
diseases caused by emerging pathogens. Members will be enabled to rapidly
discover potential treatments using small volume blood samples from recovering
patients—both acute and convalescent. The consortium is rapidly iterating and
improving the viral neutralization workflow executing on the Berkeley Lights
platform and hopes that more collaborators will come forward to participate in
fighting this epidemic and be better prepared for the next one.
"We have long sought to study the antiviral capacity of antibodies secreted by
single human B cells, but the instruments and protocols for doing those studies
didn't exist. Partnering with Berkeley Lights on developing innovative
approaches to this single-cell biology task is now becoming a reality," said
Dr. James Crowe, MD, Director of the Vanderbilt Vaccine Center.
"We have developed a specialized survival media for plasma cells and envision
the use of it for rapid upfront selection of a rare target monoclonal antibody," said Dr. Lee. "Berkeley Lights together with this consortium will make this method a reality for COVID-19
neutralizing antibodies. We hope this helps in this pandemic to save lives."
"There's an opportunity here to quickly mobilize something that could protect
frontline workers or treat those who have been infected," explained Dr.
Saphire. "Vaccines aren't available yet. Providing some immediate immunity
using antibodies could be lifesaving for those who haven't been vaccinated or
can't be vaccinated, or if the eventual vaccines aren't completely protective."
"COVID-19 is a serious threat to our health, our way of life, and the world
economy," said Dr. Eric Hobbs, CEO of Berkeley Lights. "We are committed to
doing our part by developing assays and workflows that researchers and therapeutic
developers can use to rapidly discover antibodies that are key to treatments."
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is one of the nation's largest
academic medical centers. As part of its research enterprise, in partnership
with the Vanderbilt University School of Medicine, the Vanderbilt Vaccine
Center is participating in the US Defense Advanced Research Projects Agency's
(DARPA's) Pandemic Protection Platform (P3) program, a five-year cooperative
agreement to develop protective antibody treatments that can be rushed to
health care providers within 60 days after the outbreak of viral diseases
anywhere in the world.
About La Jolla Institute for Immunology
La Jolla Institute for Immunology is dedicated to understanding the intricacies
and power of the immune system so that we may apply that knowledge to promote
human health and prevent a wide range of diseases. Since its founding in 1988
as an independent, nonprofit research organization, the Institute has made
numerous advances leading towards its goal: life without disease(R).
About Emory University
Emory University is one of the world's leading research universities. Its mission is to create,
preserve, teach and apply knowledge in the service of humanity. The Emory effort is led by
Dr. Lee of the Pulmonary, Allergy, Critical Care & Sleep Division, The Lowance Center for
Human Immunology and the Emory Vaccine Center. She contributes culture methods
developed in her lab that greatly improve the survival of B cells and plasma cells thereby
facilitating the isolation of extremely rare cells producing the antibodies of interest.
Dr. Lee's work is supported by NIH, the Lowance Center, Gates Foundation,
and the Georgia Research Alliance.
About Berkeley Lights
Here at Berkeley Lights, we think cells are awesome! Cells are capable of
manufacturing cures for diseases, fibers for clothing, energy in the form of
biofuels, and food proteins for nutrition. So the question is, if nature is
capable of manufacturing the products we need in a scalable way, why aren't we
doing more of this? Well, the answer is that with the solutions available
today, it is hard. It takes a long time to find the right cell for a specific
job, costs lots of money, and if you have picked a suboptimal cell line, has a
very low process yield. Berkeley Lights has the complete solution to find the
best cells by functionally screening and recovering individual cells for
antibody discovery, cell line development, T cell analysis, and synthetic biology.
Our proprietary technology, including the Beacon(R) and Lightning(TM) platforms
accelerate the rate you can discover and develop cell-based products in a fraction
of the time and at a fraction of the cost of conventional, legacy research methods.
Using our tools and solutions, scientists can find the best cells, the first time they look.
For more information, visit www.berkeleylights.com.
Berkeley Lights' Beacon and Lightning systems and Culture Station instrument are:
For Research Use Only. Not for use in diagnostic procedures.
Source - Berkeley Lights
CONTACT: berkeleylights@bulleitgroup.com OR For inquiries regarding the GEPAD
Consortium, please reach out to blicommunications@berkeleylights.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。